|
Clonal dynamics of aplastic anemia/paroxysmal nocturnal hemoglobinuria |
Dec 2019 |
Leukemia & Lymphoma |
Aplastic Anemia |
|
Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience |
Sep 2020 |
Leukemia & Lymphoma |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options |
Jan 2021 |
Cancer Management and Research |
Myelodysplastic Syndromes (MDS) |
|
Clinical decision‐making and treatment of myelodysplastic syndromes |
Oct 2023 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
Clinical decision-making and treatment of myelodysplastic syndromes |
Dec 2023 |
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia |
Mar 2021 |
Leukemia |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Chronic fatigue in myelodysplastic syndromes: Looking beyond anemia |
Jul 2020 |
Critical reviews in hematology/oncology |
Myelodysplastic Syndromes (MDS) |
|
Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia |
Oct 2019 |
Blood Advances |
Aplastic Anemia |
|
Characterization of Myelodysplastic Syndromes (MDS) With T-cell Large Granular Lymphocyte Proliferations (LGL) |
Jun 2020 |
Leukemia |
Myelodysplastic Syndromes (MDS) |
|
Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria |
Jan 2020 |
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
